Tag: Prescription Drugs

Displaying 1 - 20 of 216 results.

Pages

Federal Trade Commission Chairman Joe Simons issued the following statement regarding the decision by the U.S. District Court for the Eastern District of Pennsylvania in the case FTC v. AbbVie. The court ruled that AbbVie used sham litigation to illegally maintain its monopoly over the testosterone...
In an Initial Decision announced on May 18, 2018, Chief Administrative Law Judge D. Michael Chappell dismissed the antitrust charges in a complaint issued by the Federal Trade Commission against generic pharmaceutical company Impax Laboratories, Inc.
Letter From Markus H. Meier, Assistant Director, Health Care Division, Bureau of Competition, to Jennifer R. Bolster, Esq., Hancock Estabrook, LLP, Concerning Crouse Health Hospital's Proposal To Sell Discounted Pharmaceutical Products to the Employees, Retirees, and Their Dependents...
WHAT:The Federal Trade Commission will host a workshop, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics”. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr.
The staff of the Federal Trade Commission has issued an opinion advising Crouse Health Hospital that an exemption under the Non-Profit Institutions Act, or NPIA, applied to its proposal to sell discounted pharmaceutical products to the employees and retirees, as well as their dependents, of its...
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” will take place on November 8, 2017 at the FTC’s...
The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses.
The Hatch-Waxman Act, passed by Congress more than 30 years ago, provides a regulatory and judicial framework to expedite generic entry into U.S. prescription drug markets. For many drugs, the Act has succeeded in lowering patent-related barriers to generic drug entry, thereby...
Following a public comment period, the Federal Trade Commission has approved a final order designed to remedy the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business.
The Federal Trade Commission has approved a sublicense submitted by Mallinckrodt ARD Inc. granting West Therapeutic Development, LLC certain rights to develop and market the specialty drug Synacthen Depot in the United States.Synacthen Depot contains a synthetic version of adrenocorticotropic...
On January 18, 2017, the Commission settled its recent challenge to the 2013 acquisition by Questcor Pharmaceuticals, Inc. (subsequently acquired by Mallinckrodt plc) of rights to the drug Synacthen from Novartis AG.
The FTC filed a complaint in federal district court charging Shire ViroPharma Inc. with violating the antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin HCl Capsules. The complaint alleges that to maintain its...

Pages